{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T03:40:01Z","timestamp":1767757201836,"version":"3.48.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-025-04857-7","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T03:34:24Z","timestamp":1767756864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of paclitaxel premedication discontinuation on rescue medication use"],"prefix":"10.1007","volume":"96","author":[{"given":"Chang Yue","family":"Chui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bert N.","family":"Storm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise E.","family":"Sampimon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loes E.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"issue":"7","key":"4857_CR1","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","volume":"8","author":"RB Weiss","year":"1990","unstructured":"Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL et al (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8(7):1263\u20138","journal-title":"J Clin Oncol"},{"issue":"1","key":"4857_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2000.18.1.102","volume":"18","author":"M Markman","year":"2000","unstructured":"Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (2000) Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland clinic cancer center. J Clin Oncol 18(1):102\u2013105","journal-title":"J Clin Oncol"},{"issue":"7","key":"4857_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1177\/1078155216664203","volume":"23","author":"A Yenilmez","year":"2017","unstructured":"Yenilmez A, Hood AP, Nguyen LH, Merl MY (2017) Paclitaxel pre-medication: a comparison of two steroid pre-medication protocols. J Oncol Pharm Pract 23(7):491\u2013495","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"4857_CR4","first-page":"1991","volume":"20","author":"MJ Berger","year":"2012","unstructured":"Berger MJ, Dunlea LJ, Rettig AE, Lustberg MB, Phillips GS, Shapiro CL (2012) Feasibility of stopping Paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer 20(9):1991\u20131997","journal-title":"Support Care Cancer"},{"issue":"7","key":"4857_CR5","first-page":"2019","volume":"23","author":"MJ Berger","year":"2015","unstructured":"Berger MJ, Vargo C, Vincent M, Shaver K, Phillips G, Layman R et al (2015) Stopping Paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer 23(7):2019\u20132024","journal-title":"Support Care Cancer"},{"issue":"5\u20136","key":"4857_CR6","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1081\/CNV-120003535","volume":"20","author":"J Quock","year":"2002","unstructured":"Quock J, Dea G, Tanaka M, Gandara D, Lara P, Lau D (2002) Premedication strategy for weekly Paclitaxel. Cancer Invest 20(5\u20136):666\u2013672","journal-title":"Cancer Invest"},{"issue":"10","key":"4857_CR7","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1038\/s41416-021-01313-0","volume":"124","author":"JM Cox","year":"2021","unstructured":"Cox JM, van Doorn L, Malmberg R, Oomen-de Hoop E, Bosch TM, van den Bemt P et al (2021) The added value of H(2) antagonists in premedication regimens during Paclitaxel treatment. Br J Cancer 124(10):1647\u20131652","journal-title":"Br J Cancer"},{"issue":"9","key":"4857_CR8","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1158\/1078-0432.CCR-06-2347","volume":"13","author":"SA Perez","year":"2007","unstructured":"Perez SA, Karamouzis MV, Skarlos DV, Ardavanis A, Sotiriadou NN, Iliopoulou EG et al (2007) CD4\u2009+\u2009CD25\u2009+\u2009regulatory T-cell frequency in HER-2\/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res 13(9):2714\u201321","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04857-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04857-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04857-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T03:34:26Z","timestamp":1767756866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04857-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4857"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04857-7","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Due to the non-interventional nature of this study, the Dutch Medical Research Involving Human Subjects Act was not applicable, as confirmed by the medical ethics review board of Leiden-Den Haag-Delft.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"7"}}